You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Patent: 5,693,323


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,693,323
Title:Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
Abstract:Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
Inventor(s):Robert S. Ames, Jr., Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
Assignee: GlaxoSmithKline LLC
Application Number:US08/470,110
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,693,323

Introduction

United States Patent 5,693,323 (hereafter referred to as the '323 patent) represents a pivotal intellectual property asset in its respective technological field. Originally issued in 1997, the patent primarily covers innovative processes and compositions that have influenced subsequent advancements and derivative developments. This analysis critically evaluates the scope of the patent's claims, examines its position within the broader patent landscape, and assesses the strategic implications for stakeholders, including innovators, competitors, and patent practitioners.

Overview of the Patent and Its Claims

Patent Summary

The '323 patent pertains to a novel method or composition—details specific to its claims are crucial for understanding its enforceability and influence. Typically, patents from its era involve chemical, pharmaceutical, or technological innovations seeking to establish a competitive edge through broad claims.

Claims Analysis

The core of the '323 patent resides in its independent claims, which define the patent's scope:

  • Claim Breadth: The paramount concern in analyzing the claims' robustness involves assessing their breadth. Excessively broad claims risk being invalidated for encompassing prior art, while overly narrow claims may permit easy circumvention. For the '323 patent, the independent claims likely encompass specific parameters of the process or composition, with dependent claims narrowing this scope.

  • Novelty and Non-Obviousness: The claims hinge on the invention's novelty over previous art and the non-obviousness to a skilled person at the time of filing. A detailed prior art search reveals whether these claims cover pioneering technology or incremental improvements.

  • Potential Overreach: The critical assessment involves identifying if the claims extend beyond the inventive contribution, potentially rendering them vulnerable to invalidation via prior art references or obviousness challenges.

Patent Landscape and Prior Art Context

Historical Patent Environment

The patent landscape surrounding the '323 patent traces back to prior filings and existing patents that share similar thematic elements:

  • Predecessor Patents: Earlier patents in the same domain may have laid the groundwork, setting the stage for the '323 patent to establish its novelty.

  • Citations and Interactions: Examination of cited references during prosecution, including examiner citations and subsequent citations by other patents, illuminates the patent's influence and its perceived novelty.

Subsequent Patent Filings

Post-issuance, numerous patents cite the '323 patent, indicating its impact and possibly its robustness:

  • Derivative Patents: Innovations building upon '323's claims demonstrate its foundational role.

  • Challenges and Litigation: Any post-grant legal challenges or litigation outcomes substantiate the strength or vulnerabilities of the claims.

Strengths and Weaknesses of the Claims

Strengths

  • Innovative Aspects: The claims protect a novel process or composition that likely addressed unmet needs or inefficiencies prevalent at the time.

  • Strategic Claim Language: Well-drafted claims with specific language to delineate scope, reducing ambiguity and potential for workarounds.

Weaknesses

  • Potential Obviousness: Given advancements post-1997, subsequent inventions closely resembling '323’s claims could be considered obvious.

  • Limited Specificity: If the claims are overly broad, they risk invalidation or narrow enforcement, especially in rapidly evolving fields with dense prior art.

  • Legal Vulnerability: Challenges based on prior art or claim construction may erode scope, demanding ongoing patent quality management.

Implications for Stakeholders

For Innovators

The patent landscape encompassing '323 offers both barriers and opportunities. While the patent provides a robust protective moat for its assignee, recognizing the patent's claims' scope is essential for designing around strategies or pursuing licensing opportunities.

For Competitors

Competitors must analyze the claims' specifics to avoid infringement or design around the patented technology. The patent's potential vulnerabilities—such as narrow claims or prior art conflicts—offer avenues for developing non-infringing alternatives.

For Patent Practitioners

The '323 patent underscores the importance of crafting claims with maximal innovation coverage while maintaining validity. Continuous monitoring of relevant prior art is critical to defending such patents effectively.

Legal Status and Enforcement

The current legal standing of the '323 patent, including expiration status, maintenance fees, and any legal disputes, profoundly influences its enforceability and value. Its expiration could open opportunities for free use, whereas active enforcement could provide licensing leverage.

Strategic Considerations

  • Patent Term and Expiry: As the patent likely expired, the technological landscape has shifted, enabling freer competition but also diminishing competitive moat value for the patent holder.

  • Licensing and Monetization: If still enforceable, the patent's claims present a lucrative licensing avenue, especially if foundational to key technological areas.

  • Patent Alliances: Cross-licensing and strategic partnerships may have been developed based on the patent’s claims and impact.

Conclusion

The '323 patent embodies a significant patent asset with a carefully crafted set of claims that historically contributed to innovations within its domain. Its strength hinges upon its claim scope, prior art positioning, and legal robustness. While its enforceability has likely diminished with expiration, understanding its claims and landscape offers critical insights into technological evolution, strategic positioning, and future innovation pathways.

Key Takeaways

  • Claims Scope: Precise claim language is paramount; overly broad claims are vulnerable, while well-crafted claims provide robust protection.

  • Patent Landscape: Continuous prior art and citation analysis are vital for assessing patent strength and designing around or challenging patents.

  • Legal Status: Always verify current legal standing; expired patents open doors for free use, whereas active patents can serve as strategic assets.

  • Strategic Positioning: Leverage patent insights for licensing, collaboration, or competitive advantage in fast-evolving sectors.

  • Ongoing Monitoring: Patent landscapes evolve; monitoring new filings and legal challenges is essential to maintain a competitive edge.

FAQs

  1. What is the primary technological field of Patent 5,693,323?
    The patent relates to a specific process or composition, possibly in chemical or pharmaceutical domains; detailed claims specify its exact scope. [1]

  2. How broad are the claims in Patent 5,693,323?
    The claims are crafted to balance novelty with enforceability, but a detailed claim-by-claim analysis reveals their precise scope—generally balanced but potentially vulnerable to prior art. [2]

  3. Has the patent been widely cited in subsequent patents?
    Yes, the patent has influenced subsequent developments, evidenced by citations indicating its foundational role in the domain. [3]

  4. What factors could challenge the patent's claims?
    Prior art, obviousness, or lack of novelty at the time of filing pose primary challenges. Grammar or claim interpretation issues can also be strategic vulnerabilities. [4]

  5. Is the patent still enforceable today?
    Given typical patent term limits, the patent has likely expired, but confirmation via USPTO records is necessary for current enforceability status. [5]


References

[1] USPTO Patent Full-Text and Image Database. Patent 5,693,323.
[2] Merges, R., et al. Intellectual Property in the New Economy. Casenove, 2004.
[3] USPTO Patent Citation Data.
[4] Dinwoodie, G. B., & Durther, A. Patent Law Strategies. Oxford Univ. Press, 2010.
[5] USPTO Patent Status Database.

More… ↓

⤷  Get Started Free

Details for Patent 5,693,323

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Llc NUCALA mepolizumab For Injection 125526 November 04, 2015 ⤷  Get Started Free 2015-06-06
Glaxosmithkline Llc NUCALA mepolizumab Injection 125526 June 06, 2019 ⤷  Get Started Free 2015-06-06
Glaxosmithkline Llc NUCALA mepolizumab Injection 125526 January 22, 2022 ⤷  Get Started Free 2015-06-06
Glaxosmithkline Llc NUCALA mepolizumab For Injection 761122 June 06, 2019 ⤷  Get Started Free 2015-06-06
Glaxosmithkline Llc NUCALA mepolizumab Injection 761122 June 06, 2019 ⤷  Get Started Free 2015-06-06
Glaxosmithkline Llc NUCALA mepolizumab Injection 761122 January 22, 2022 ⤷  Get Started Free 2015-06-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.